同时辅助治疗疟疾及其共同进化的遗传病镰状细胞贫血
该研究探讨羟基脲(HU)治疗镰状细胞贫血(SCA)时对恶性疟原虫感染的影响,采用模拟人体内药代动力学的体外实验,发现HU及其他核糖核苷酸还原酶抑制剂对正常和镰状红细胞内的疟原虫裂殖体期有内在杀伤活性,长期选择后耐药风险低,且与多种抗疟药呈相加活性。
要点
- HU治疗SCA可降低临床并发症、输血和死亡率。
- HU及其他RNR抑制剂在体外对恶性疟原虫裂殖体期有内在杀伤活性。
- HU与常用抗疟药呈相加活性,长期体外选择耐药风险低。
核心结论
- HU可安全有效地治疗SCA,在疟疾流行国家可广泛、安全、长期使用。
- HU及其他RNR抑制剂对恶性疟原虫裂殖体期有内在杀伤活性,且与抗疟药呈相加活性。
研究设计与样本
- 采用模拟人体内药代动力学的生理相关药物暴露进行体外研究。
- 在正常和镰状红细胞中测试HU及其他RNR抑制剂对恶性疟原虫裂殖体期的杀伤活性。
- 进行长期体外选择实验评估耐药风险。
主要发现
- HU减少临床疟疾而非增加感染风险。
- HU及其他RNR抑制剂对正常和镰状红细胞中的恶性疟原虫裂殖体期均有显著内在杀伤活性。
- 长期体外选择增加Pfrnr基因表达,但引发稳定耐药寄生虫的风险低,且不损害当前抗疟药效力。
- HU与多种常用抗疟药呈相加活性,无拮抗作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Effective treatments for genetic disorders that coevolved with pathogens require simultaneous betterment of both conditions. Hydroxyurea (HU) offers safe and efficacious treatment for sickle cell anemia (SCA) by reducing clinical complications, transfusions, and death rates. Despite concerns that the HU treatment for SCA would increase infection risk by the human malaria Plasmodium falciparum, (the genetic driver of the sickle mutation), HU instead reduced clinical malaria. We used physiologically relevant drug exposures that mimic in vivo pharmacokinetics in humans. Under these conditions, we showed that HU and other ribonucleotide reductase (RNR) inhibitors have significant, intrinsic killing activity in vitro against schizont stages of P falciparum in both normal and sickle red blood cells. Long-term in vitro selection with HU increased the expression of Pfrnr genes but showed a low risk of eliciting stably resistant parasites or compromising the potency of current antimalarial drugs. Additive activity devoid of antagonism by HU was observed with a wide spectrum of commonly used antimalarial treatments. These data endorse broad, safe, and long-term use of HU for SCA in malaria-endemic countries and provide a novel biological model for the treatment of a genetic disorder with simultaneous, adjunct therapy of a life-threatening infection needed in a global health setting.
引用
- Safeukui I, Ware RE, Mohandas N, et al. Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood Adv. 2023. PMID: 37093647. doi:10.1182/bloodadvances.2022009124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。